| Quality assessment | No of patients | Effect | Quality | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| No of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Gemcitabine, carboplatin, docetaxel | Control | Relative (95% CI) | Absolute | |
| Overall survival | |||||||||||
| 11 | observational studies | none | none | serious2 | serious3 | none | N=26 | - | Median OS = 12.6 months | ⊕○○○ VERY LOW | |
| Progression-free survival | |||||||||||
| 11 | observational studies | none | none | serious2 | serious3 | none | N=26 | - | Median PFS = 5 months | ⊕○○○ VERY LOW | |
| Overall tumour response (assessed with: RECIST) | |||||||||||
| 11 | observational studies | none | none | serious2 | serious3 | none | 9/16 (56.3%)4 | - | - | - | ⊕○○○ VERY LOW |
| Grade 3-4 Neutropenia (assessed with: NCI-CTC) | |||||||||||
| 11 | observational studies | none | none | serious2,5 | serious3 | none | 28/35 (80%) | - | - | - | ⊕○○○ VERY LOW |
| Grade 3-4 Thrombocytopenia (assessed with: NCI-CTC) | |||||||||||
| 11 | observational studies | none | none | serious2,5 | serious3 | none | 18/35 (51.4%) | - | - | - | ⊕○○○ VERY LOW |
| Grade 3-4 Anaemia (assessed with: NCI-CTC) | |||||||||||
| 11 | observational studies | none | none | serious2,5 | serious3 | none | 15/35 (42.9%) | - | - | - | ⊕○○○ VERY LOW |
| Treatment-related mortality (assessed with: NCI-CTC) | |||||||||||
| 11 | observational studies | none | none | serious2 | serious3 | none | 0/35 (0%) | - | - | - | ⊕○○○ VERY LOW |
| Health-related quality of life | |||||||||||
| 0 | No evidence available | ||||||||||
Neoadjuant and adjuvant chemotherapy considered as first-line chemotherapy;
Small sample size / low number of events limit the precision of this outcome
Excluded participants who received combination radiation therapy;
Toxicity data not reported separately for 2nd line chemotherapy patients
From: 5, Managing locally advanced or metastatic bladder cancer
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.